company background image
MRTX

Mirati Therapeutics NasdaqGS:MRTX Stock Report

Last Price

US$98.62

Market Cap

US$5.7b

7D

28.5%

1Y

-27.9%

Updated

27 Nov, 2022

Data

Company Financials +
MRTX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

MRTX Stock Overview

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States.

Mirati Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mirati Therapeutics
Historical stock prices
Current Share PriceUS$98.62
52 Week HighUS$154.17
52 Week LowUS$32.96
Beta0.83
1 Month Change45.22%
3 Month Change31.21%
1 Year Change-27.89%
3 Year Change-2.13%
5 Year Change488.78%
Change since IPO1,060.24%

Recent News & Updates

We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth

Oct 08
We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth

Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?

Sep 11
Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?

Recent updates

We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth

Oct 08
We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth

Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?

Sep 11
Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

Aug 08
Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

Need To Know: The Consensus Just Cut Its Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates For 2022

May 29
Need To Know: The Consensus Just Cut Its Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates For 2022

We're Hopeful That Mirati Therapeutics (NASDAQ:MRTX) Will Use Its Cash Wisely

May 27
We're Hopeful That Mirati Therapeutics (NASDAQ:MRTX) Will Use Its Cash Wisely

Analyst Forecasts Just Became More Bearish On Mirati Therapeutics, Inc. (NASDAQ:MRTX)

Feb 10
Analyst Forecasts Just Became More Bearish On Mirati Therapeutics, Inc. (NASDAQ:MRTX)

We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth

Jan 31
We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Shares Could Be 48% Below Their Intrinsic Value Estimate

Oct 23
Mirati Therapeutics, Inc. (NASDAQ:MRTX) Shares Could Be 48% Below Their Intrinsic Value Estimate

News Flash: 10 Analysts Think Mirati Therapeutics, Inc. (NASDAQ:MRTX) Earnings Are Under Threat

Aug 08
News Flash: 10 Analysts Think Mirati Therapeutics, Inc. (NASDAQ:MRTX) Earnings Are Under Threat

Here's Why We're Not Too Worried About Mirati Therapeutics' (NASDAQ:MRTX) Cash Burn Situation

Jul 25
Here's Why We're Not Too Worried About Mirati Therapeutics' (NASDAQ:MRTX) Cash Burn Situation

Analysts' Revenue Estimates For Mirati Therapeutics, Inc. (NASDAQ:MRTX) Are Surging Higher

Jun 02
Analysts' Revenue Estimates For Mirati Therapeutics, Inc. (NASDAQ:MRTX) Are Surging Higher

Shareholders May Not Be So Generous With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) CEO Compensation And Here's Why

May 06
Shareholders May Not Be So Generous With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) CEO Compensation And Here's Why

We're Not Very Worried About Mirati Therapeutics' (NASDAQ:MRTX) Cash Burn Rate

Apr 19
We're Not Very Worried About Mirati Therapeutics' (NASDAQ:MRTX) Cash Burn Rate

Analysts Have Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenue Estimates By 40%

Mar 14
Analysts Have Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenue Estimates By 40%

Have Mirati Therapeutics, Inc. (NASDAQ:MRTX) Insiders Been Selling Their Stock?

Mar 10
Have Mirati Therapeutics, Inc. (NASDAQ:MRTX) Insiders Been Selling Their Stock?

Newsflash: Mirati Therapeutics, Inc. (NASDAQ:MRTX) Analysts Have Been Trimming Their Revenue Forecasts

Feb 27
Newsflash: Mirati Therapeutics, Inc. (NASDAQ:MRTX) Analysts Have Been Trimming Their Revenue Forecasts

Are Insiders Selling Mirati Therapeutics, Inc. (NASDAQ:MRTX) Stock?

Feb 15
Are Insiders Selling Mirati Therapeutics, Inc. (NASDAQ:MRTX) Stock?

We're Hopeful That Mirati Therapeutics (NASDAQ:MRTX) Will Use Its Cash Wisely

Jan 11
We're Hopeful That Mirati Therapeutics (NASDAQ:MRTX) Will Use Its Cash Wisely

A Look At The Intrinsic Value Of Mirati Therapeutics, Inc. (NASDAQ:MRTX)

Dec 03
A Look At The Intrinsic Value Of Mirati Therapeutics, Inc. (NASDAQ:MRTX)

Shareholder Returns

MRTXUS BiotechsUS Market
7D28.5%0.4%1.3%
1Y-27.9%-14.4%-18.5%

Return vs Industry: MRTX underperformed the US Biotechs industry which returned -14.4% over the past year.

Return vs Market: MRTX underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is MRTX's price volatile compared to industry and market?
MRTX volatility
MRTX Average Weekly Movement9.8%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: MRTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: MRTX's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1995413David Meekhttps://www.mirati.com

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd.

Mirati Therapeutics, Inc. Fundamentals Summary

How do Mirati Therapeutics's earnings and revenue compare to its market cap?
MRTX fundamental statistics
Market CapUS$5.68b
Earnings (TTM)-US$738.01m
Revenue (TTM)US$11.80m

481.3x

P/S Ratio

-7.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MRTX income statement (TTM)
RevenueUS$11.80m
Cost of RevenueUS$0
Gross ProfitUS$11.80m
Other ExpensesUS$749.81m
Earnings-US$738.01m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-12.82
Gross Margin100.00%
Net Profit Margin-6,253.81%
Debt/Equity Ratio0%

How did MRTX perform over the long term?

See historical performance and comparison